

## Special Issue

# Feature Papers in Cancer Biology and Anticancer Therapeutics

### Message from the Guest Editor

Cancer is a complex disease involving genetic/epigenetic alterations and multiple pathogenetic mechanisms. Investigation of the differential characteristics of various types of cancer cells, which distinguish them from normal cells, allows for the identification of cancer-specific targets. The principle of cancer chemo- and immune-therapies is based on the molecular targeting of the vulnerabilities of cancer cells inducing cell death by apoptosis. In this Special Issue, we focus attention on novel target-based anticancer agents and therapeutics that exploit the vulnerabilities of cancer cells. We welcome the submission of research and review articles on the development of new anticancer agents and therapeutics.

---

### Guest Editor


Prof. Dr. Seiichi Tanuma

1. Department of Genomic Medicinal Science, Research Institute for Science and Technology, Organization for Research Advancement, Tokyo University of Science, Noda, Chiba 278-8510, Japan
2. Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan

---

### Deadline for manuscript submissions

closed (31 May 2021)



## Medicines

---

an Open Access Journal  
by MDPI

---

Indexed in PubMed




[mdpi.com/si/65901](https://mdpi.com/si/65901)

*Medicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[medicines@mdpi.com](mailto:medicines@mdpi.com)

[mdpi.com/journal/  
medicines](https://mdpi.com/journal/medicines)





# Medicines

---

an Open Access Journal  
by MDPI

---

Indexed in PubMed



[mdpi.com/journal/  
medicines](https://mdpi.com/journal/medicines)



## About the Journal

### Message from the Editor-in-Chief

*Medicines* (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

---

### Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1  
Keyakidai, Sakado, Saitama 350-0283, Japan

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 30.6 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the first half of 2026).